Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion

Bibliography

• Padsis J, Turley R, Tyler D. Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2010;11(1):79-93
   PubMed Web of Science ®Google Scholar
• Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008;15(3):225-32
   PubMedGoogle Scholar
• Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010;16(2):132-41
   PubMed Web of Science ®Google Scholar
• Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999;36(11):841-907
   PubMedGoogle Scholar
• Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989;169(1):1-6
   PubMedGoogle Scholar
• Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44(11):4651-9
   PubMed Web of Science ®Google Scholar
• Becker JC, Terheyden P, Kampgen E, Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87(8):840-5
   PubMed Web of Science ®Google Scholar
• Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983;52(2):334-6
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98(3):383-9; discussion 390
   PubMed Web of Science ®Google Scholar
• Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;p73(4):340-4
   Google Scholar
• Kath R, Hayungs J, Bornfeld N, Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72(7):2219-23
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Legha SS, Mavligit G, Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76(9):1665-70
   PubMed Web of Science ®Google Scholar
• Zogakis TG, Bartlett DL, Libutti SK, Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8(10):771-8
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN, Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115(1):39-45
   PubMed Web of Science ®Google Scholar
• Minor DR, Allen RE, Alberts D, A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55(11):2638-44
   PubMed Web of Science ®Google Scholar
• Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007;245(4):591-6
   PubMed Web of Science ®Google Scholar
• Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15(11):3003-13
   PubMed Web of Science ®Google Scholar
• Beasley GM, Petersen RP, Yoo J, Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15(8):2195-205
   PubMed Web of Science ®Google Scholar
• Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010;37(2):127-38
   PubMed Web of Science ®Google Scholar
• Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30(5):969-77
   PubMed Web of Science ®Google Scholar
• Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004;11(3):290-7
   PubMed Web of Science ®Google Scholar
• Beheshti MV, Denny DF Jr, Glickman MG, Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. J Vasc Interv Radiol 1992;3(3):453-8
   PubMedGoogle Scholar
• Weinreich DM, Alexander HR. Transarterial perfusion of liver metastases. Semin Oncol 2002;29(2):136-44
   PubMed Web of Science ®Google Scholar
• Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;S1:45-50
   Google Scholar
• Lindner P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36
   PubMed Web of Science ®Google Scholar
• McMahon N, Cheng TY, Beasley GM, Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16(4):953-61
   PubMed Web of Science ®Google Scholar
• Cheng TY, Grubbs E, Abdel-Wahab O, Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003;186(5):460-7
   PubMed Web of Science ®Google Scholar
• Thompson JF, Morton DL, Kroon BBR. editors. Isolated limb perfusion for melanoma: technical aspects. Martin Dunitz; London: 2004. p. 404-9
   Google Scholar
• Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Biol Relat Stud Phys Chem Med 1991;20:287-9
   Google Scholar
• Van der Merwe SA, Van der berg AP, Kroon BB, Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 1993;9:205-17
   PubMed Web of Science ®Google Scholar
• Raymond AK, Beasley GM, Broadwater G, Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Amer Coll Surg 2011;213(2):306-16
   PubMed Web of Science ®Google Scholar
• Fletcher WS, Pommier RF, Small K. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res 1994;4(Suppl 1):17-19
   PubMedGoogle Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30(10):1107-12
   PubMed Web of Science ®Google Scholar
• Hochster H, Strawderman MH, Harris JE, Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study. Anticancer Drug Des 1999;10:2r45
   Google Scholar
• Parsons PG, Carter FB, Morrison L, Mary SR. Mechanism of melphalan resistance development in human melanoma cell lines. Cancer Res 1981;41:1525-3
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, deWilt J, Graveland WJ, Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:1776-84
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Abdel-Wahab O, Cheng TY, In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004;199(3):419-27
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E, Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004;188(5):532-7
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuijsen C, Braat RP. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10
   PubMedGoogle Scholar
• Benckhuijsen C, Kroon BBR, van Geel AN, Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157
   PubMed Web of Science ®Google Scholar
• Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharm Exp Ther 1997;282(3):1131-8
   PubMed Web of Science ®Google Scholar
• Thompson JF, Ramzan I, Kam PCA, Clinical pharmacokinetics of melphalan during isolated limb perfusion: compartmental modeling and moment analysis. Reg Cancer Treat 1995;8:83-7
   Google Scholar
• Scott RN, Blackie R, Kerr DJ, Melphalan concentration and distribution in the tissues of tumuor-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992;11:1811-13
   Google Scholar
• Thompson JF, Siebert GA, Anissimov YG, Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001;85(2):157-65
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Thrall DE, Palmer G, Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. Int J Hyperthermia 2010;26(3):283-93
   PubMed Web of Science ®Google Scholar
• Baur A, Stabler A, Wendtner CM, MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia 2003;19:391-401
   PubMed Web of Science ®Google Scholar
• Roberts MS, Wu ZY, Siebert GA, Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001;11(4):423-31
   PubMed Web of Science ®Google Scholar
• Santillan AA, Delman KA, Beasley GM, Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16(9):2570-8
   PubMed Web of Science ®Google Scholar
• Roberts MS, Wu ZY, Siebert GA, Saturable dose-response relationships for melphalan in melanoma treated by isolated limb infusion in the nude rat. Melanoma Res 2001;11(6):611-18
   PubMed Web of Science ®Google Scholar
• Harada N, Nagasaki A, Hata H, Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2001;103:144-51
   Web of Science ®Google Scholar
• Grubbs EG, Ueno T, Abdel-Wahab O. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004;136(2):210-18
   PubMed Web of Science ®Google Scholar
• Eder JP Jr, Chan VT, Ng SW, DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 1995;55:6109-16
   PubMed Web of Science ®Google Scholar
• Komdeur R, Platt BE, Hoekstra HJ, Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 2001;91(10):1940-8
   PubMed Web of Science ®Google Scholar
• Clark J, Grabs A, Parsons PG, Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma Melanoma Res. 1994;4:365-70
   Google Scholar
• Abdel-Wahab OI, Grubbs E, Viglianti B. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004;10(17):5919-29
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia 2010;12:889-98
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65
   PubMed Web of Science ®Google Scholar
• Augustine CK, Yoshimoto Y, Gupta M. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68(10):3777-84
   PubMed Web of Science ®Google Scholar
• Toshimitsu H, Padussis J, Turley R, Targeting N-cadherin to augment the efficacy of regional chemotherapy: a potential double- edged sword? Ann Surg Oncol 2010;17:S1
   PubMedGoogle Scholar
• Beasley GM, Riboh J, Augustine CK, Prospective Multicenter Phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 2011; Epub ahead of print
   Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
   PubMed Web of Science ®Google Scholar
• Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-32
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MA, Wen PY, Bevacizumab Alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50
   PubMed Web of Science ®Google Scholar
• Turley RS, Padussis JC, Toshimitsu Y, Bevacizumab-induced vascular remodeling augments regional chemotherapy for intransit melanoma. 2011; in preparation
   Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Stein MN, Flaherty KJ. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-70
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carte C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK path- way and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA, Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21
   PubMed Web of Science ®Google Scholar
• Augustine CK, Toshimitsu H, Jung SH, Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 2010;9(7):2090-101
   PubMed Web of Science ®Google Scholar
• McMahon N, Beasley GM, Sanders G, A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. J Clin Oncol 2009;27(15s):abstract 9065
   Google Scholar
• Jilaveanu L, Zito C, Lee SJ, Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009;15:1076-85
   PubMed Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24(25):4196-201
   PubMed Web of Science ®Google Scholar
• Sadadcharam M, Soden DC, O'Sullivan GC. Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 2008;24(3):263-73
   PubMed Web of Science ®Google Scholar
• Ramirez LH, Orlowski S, An D, Electrochemotherapy on liver tumors in rabbits. Br J Cancer 1998;77:2104-11
   PubMed Web of Science ®Google Scholar
• Sersa G, Cemazar M, Miklavic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999;19:4017-22
   PubMed Web of Science ®Google Scholar
• Marty MSG, Sersa G, Garbay JR. Electrochemotherapy: an easy highly effective and safe treatment of cutaneous and subcutaneous metastases. Results of ESOPE. Eur J Cancer 2006;4S:3-13
   Google Scholar
• Ravikumar TS, Pizzorno G, Bodden W, Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12(12):2723-36
   PubMed Web of Science ®Google Scholar
• Curley SA, Newman RA, Dougherty TB, Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994;1(5):389-99
   PubMed Web of Science ®Google Scholar
• Pingpank JF, Libutti SK, Chang R, Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23(15):3465-74
   PubMed Web of Science ®Google Scholar
• Alexander HR Jr, Libutti SK, Pingpank JF, Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003;9(17):6343-9
   PubMed Web of Science ®Google Scholar
• Pingpank JF, Hughes MS, Alexander HR, A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. Presented at the American Society of Clinical Oncology, 2010
   Google Scholar
• Miao N, Pingpank JF, Alexander HR, Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008;15(3):815-23
   PubMed Web of Science ®Google Scholar